The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Progression-free survival after second line of therapy (PFS-2) for metastatic clear cell renal cell carcinoma (ccRCC) in patients treated with first-line immunotherapy combinations.
 
Kelly N. Fitzgerald
No Relationships to Disclose
 
Cihan Duzgol
No Relationships to Disclose
 
Andrea Knezevic
Consulting or Advisory Role - ByHeart
 
Natalie Shapnik
No Relationships to Disclose
 
Ritesh Kotecha
Consulting or Advisory Role - Eisai
Research Funding - Pfizer (Inst); Takeda (Inst)
 
David Henry Aggen
Consulting or Advisory Role - Astellas Pharma; Boehringer Ingelheim; Seagen
Patents, Royalties, Other Intellectual Property - University of Illinois - Urbana Champaign
 
Maria Isabel Carlo
Other Relationship - Prostate Cancer Foundation; Robert Wood Johnson Foundation
 
Neil J. Shah
Consulting or Advisory Role - Merck Sharp & Dohme Corp.
Research Funding - Aravive (Inst)
Travel, Accommodations, Expenses - Merck
 
Martin H Voss
Stock and Other Ownership Interests - CellGenix (I)
Consulting or Advisory Role - Affimed Therapeutics; AVEO; Calithera Biosciences; Eisai; Exelixis; Genentech; Merck; Oncorena; OnQuality Pharmaceuticals; Pfizer
Research Funding - Pfizer
Other Relationship - BMS
(OPTIONAL) Uncompensated Relationships - Aravive; BMS; Genentech/Roche
 
Darren R. Feldman
Consulting or Advisory Role - Cigna
Research Funding - Astellas Pharma; Decibel Therapeutics (Inst); Seagen
Other Relationship - UpToDate
 
Robert J. Motzer
Consulting or Advisory Role - AstraZeneca; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Genentech/Roche; Incyte; Lilly; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Chung-Han Lee
Honoraria - American Institute of Continuing Medical Education; Intellisphere; Research to Practice
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Exelixis; Merck; Pfizer/EMD Serono
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Exelixis (Inst); Merck (Inst)